Advertisement
Fewer than half of Americans are aware that some major lifestyle factors can affect their cancer risk

AICR: Awareness of Key Cancer Risk Factors Alarmingly Low

0
Many worry about unproven factors like food additives; less about exercise and obesity

January 2015 Briefing – Gastroenterology

0
Here are what the editors at HealthDay consider to be the most important developments in Gastroenterology for January 2015. This roundup includes the latest...
Patient engagement initiatives can decrease costs without sacrificing quality care

Patient Engagement Can Cut Costs, Improve Outcomes

0
Initiatives can decrease hospital visits, cut morbidity and mortality, up treatment adherence
For liver transplantation recipients with model for end-stage liver disease scores above 11

Decreasing Serum Sodium Ups Liver Transplant Survival

0
Survival benefit for patients with MELD >11; no benefit seen for patients with MELD scores of ≤11
Although the overall rate of colorectal cancer has fallen in recent decades

Colorectal Cancer Rates on Rise in Young Americans

0
Still, only 10 percent of cases occur in younger group, researchers find
From 2002 to 2011 there was a decrease in the rate of hospitalizations for hepatitis A

Hepatitis A Hospitalizations Down From 2002 to 2011

0
Increase in age of those hospitalized, and in percent of hospitalizations covered by Medicare
Nearly one in 10 American adults don't take their medications as prescribed because they can't afford to

CDC: ~8 Percent of U.S. Adults Nonadherent Due to Rx Costs

0
Patients skipping doses, taking less medication or delaying filling prescriptions
For adult patients with Crohn's disease

Meta-Analysis Compares Tx for Inducing Remission in Crohn’s

0
Adalimumab and infliximab + azathioprine most effective for induction, maintenance of remission
The positive rate of the glucose breath test is higher in patients with inflammatory bowel disease

Glucose Breath Test Positivity Up in Inflammatory Bowel Disease

0
Positive rate significantly higher in patients with Crohn's disease; positivity linked to GI symptom
The first generic version of Nexium (esomeprazole magnesium delayed-release capsules) has been approved by the U.S. Food and Drug Administration to treat gastroesophageal reflux disease in adults and children ages 1 and older.

FDA Approves Generic Form of Nexium

0
To treat gastroesophageal reflux disease in adults and children ages 1 and older